title: A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
abstract: As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25 mg/m2 by CIV days 1-5, fludarabine 15 mg/m2 and ara-C 0.5 g/m2 IV, BID, on days 2-6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML.
authors.affiliation: Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Box 428, 1400 Holcombe Boulevard, Houston, TX 77030, USA. frankgiles@aol.com
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Cortes
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.forename: Susan M
authors.initials: SM
authors.lastname: O'Brien
authors.forename: Elihu
authors.initials: E
authors.lastname: Estey
authors.forename: Miloslav
authors.initials: M
authors.lastname: Beran
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D003561:Cytarabine; D019772:Topotecan; D014740:Vidarabine; C024352:fludarabine